Following positive phase 2 results from its ready-to-use liquid formulation botulinum toxin, global pharmaceutical company Galderma has received a manufacturing license from the Swedish Medical Products Agency (MPA) for a new state-of-the-art manufacturing facility at the Center of Excellence, located in Uppsala, Sweden.
This new facility is designed exclusively to meet the production and safety requirements of QM1114 liquid formulation of botulinum toxin type A. It will also ensure that Galderma can meet increasing worldwide demand as the company's aesthetic portfolio grows.
According to Galderma, the investment in the development of QM1114 is evidence of the company's ongoing commitment to advancing the field of medical aesthetics through innovative solutions that create positive impact for aesthetics providers and their patients.
"Innovation is at the core of our business and our investment is backed by a trusted legacy of creating unique solutions that meet our customer needs," said Alexandre Brennan, global head of aesthetics, Galderma. He added, "We are proud to be leaders in toxin research, and with these studies for a novel liquid formulation of botulinum toxin type A, we are building on our aesthetics heritage by advancing new treatments at our Center of Excellence in Sweden."
Phase 3 trials for Galderma's liquid formulation of botulinum toxin type A for the treatment of glabellar lines are expected to begin soon and will involve approximately 1,500 subjects.